Literature DB >> 2336298

Studies on Pneumococcus vaccine alone or mixed with DTP and on Pneumococcus type 6B and Haemophilus influenzae type b capsular polysaccharide-tetanus toxoid conjugates in two- to five-year-old children with sickle cell anemia.

S Sarnaik1, J Kaplan, G Schiffman, D Bryla, J B Robbins, R Schneerson.   

Abstract

Pneumococcus vaccine, injected alone or mixed with diphtheria-tetanus toxoid-pertussis, did not elicit significant concentrations of pneumococcus type 6 antibodies in 2- to 5-year-old sickle cell anemia patients (n = 22). Reinjection 5 months later failed to elicit a booster response to pneumococcus type 6. We then injected conjugates of pneumococcus type 6B and of Haemophilus influenzae type b (Hib), each bound to tetanus toxoid (TT), alternatively at monthly intervals into sickle cell anemia patients of the same age group (n = 25); most received 3 injections of each vaccine. Pneumococcus vaccine was administered to 19 patients and Hib to 1 at approximately 1 year of age. Blood samples were taken before each and approximately 6 months after the last injection. Infrequent and minimal local reactions and only 6 episodes of fever (3%) occurred after injection of the conjugates. Pneumococcus type 6B-TT elicited a rise in the geometric mean concentration of pneumococcus type 6 antibodies (Ab) from 104 ng of antibody nitrogen (AbN)/ml in preimmunization sera to 385 ng of AbN/ml after the first injection (P less than 0.01). There were further increases after the 2 subsequent injections; 6 months after the third injection, the mean concentration was 940 ng of AbN/ml and 15 of 16 (94%) had greater than 300 ng of AbN/ml. Hib-TT elicited a 160-fold increase of Hib antibodies to a geometric mean concentration of 39.0 micrograms of Ab/ml after the first injection. These levels rose approximately 2-fold following 2 additional injections to 71.7 micrograms/ml and declined to 10.7 micrograms/ml at the 6-month sampling.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2336298     DOI: 10.1097/00006454-199003000-00007

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  14 in total

Review 1.  Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides.

Authors:  Catherine M Wernette; Carl E Frasch; Dace Madore; George Carlone; David Goldblatt; Brian Plikaytis; William Benjamin; Sally A Quataert; Steve Hildreth; Daniel J Sikkema; Helena Käyhty; Ingileif Jonsdottir; Moon H Nahm
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

2.  Synthesis and immunogenicity evaluation of Salmonella enterica serovar Paratyphi A O-specific polysaccharide conjugated to diphtheria toxoid.

Authors:  Aamir Ali; So J An; Changfa Cui; Abdul Haque; Rodney Carbis
Journal:  Hum Vaccin Immunother       Date:  2014-03-06       Impact factor: 3.452

3.  Purification and immunogenicity of genetically obtained pneumolysin toxoids and their conjugation to Streptococcus pneumoniae type 19F polysaccharide.

Authors:  J C Paton; R A Lock; C J Lee; J P Li; A M Berry; T J Mitchell; P W Andrew; D Hansman; G J Boulnois
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

4.  The pneumococcus: host-organism interactions and their implications for immunotherapy and immunoprophylaxis.

Authors:  F E Perry; J R Catterall
Journal:  Thorax       Date:  1994-10       Impact factor: 9.139

5.  Phase 1 and phase 2 studies of Salmonella enterica serovar paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam.

Authors:  E Y Konadu; F Y Lin; V A Hó; N T Thuy; P Van Bay; T C Thanh; H B Khiem; D D Trach; A B Karpas; J Li; D A Bryla; J B Robbins; S C Szu
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

Review 6.  Use of licensed vaccines for active immunization of the immunocompromised host.

Authors:  L A Pirofski; A Casadevall
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

7.  Antibody responses to Haemophilus influenzae type b conjugate vaccine in sickle cell disease.

Authors:  D Goldblatt; M Johnson; J Evans
Journal:  Arch Dis Child       Date:  1996-08       Impact factor: 3.791

8.  Detection of Haemophilus influenzae type b by real-time PCR.

Authors:  Adrian Marty; Oliver Greiner; Philip J R Day; Sibylle Gunziger; Kathrin Mühlemann; David Nadal
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

9.  Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines.

Authors:  S C Szu; D N Taylor; A C Trofa; J D Clements; J Shiloach; J C Sadoff; D A Bryla; J B Robbins
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

10.  On the power of chemical synthesis: immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines.

Authors:  Govindaswami Ragupathi; Don M Coltart; Lawrence J Williams; Fusataka Koide; Ella Kagan; Jennifer Allen; Christina Harris; Peter W Glunz; Philip O Livingston; Samuel J Danishefsky
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.